Swiss biotech Nouscom has closed a €120 million ($135 million) fourth-round financing for a vaccine to protect people with a ...

Shares in Neurocrine Bioscience took a tumble after the company reported mid-stage data for a key pipeline drug for schizophrenia that failed to impress investors. The 19% after-market selloff came ...

According to an update on the clinicaltrials.gov registry website, Novartis has terminated the study of Fabhalta (iptacopan) ...

The EMA's human medicines committee, the CHMP, has recommended approval of Eli Lilly's oral GLP-1 agonist Foundayo for weight ...

From patient engagement apps to clinical trial management platforms, development teams are increasingly turning to AI coding ...

City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference (RNAi) therapies headed by a ...

The CHMP has backed Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who have received at least ...

August and September brought leadership changes across healthcare communications, consulting, investment, and industry ...

"Treating thyroid eye disease requires balancing efficacy, safety, and the practical realities of long-term treatment," said ...

Saunders' latest spell as CEO started in 2023, as Bausch Health worked to spin Bausch + Lomb out as an independent public ...

Although real progress has been made in managing depression over recent decades, significant hurdles remain. In fact, around ...

As it waits for an FDA decision on one non-opioid pain drug, Viatris has its eye on two more, via a takeover bid for Pacira ...